Teriflunomide is a novel, oral immunomodulatory drug recently approved in the USA and Australia as a treatment for relapsing MS (RMS). In the DA rat model of MS it delays the onset and progression of EAE (Merrill et al., 2009) . Teriflunomide selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, required for de novo pyrimidine synthesis (Warnke et al., 2009) . Blocking de novo pyrimidine synthesis results in the inhibition of cell proliferation, which consequently prevents the expansion of stimulated T and B cells. However, slowly dividing or resting cells, which rely on the salvage pathway for pyrimidine synthesis, are relatively unaffected by teriflunomide, thereby maintaining homeostatic proliferation and availability of cells for immune surveillance (Gold and Wolinsky, 2011) .
Teriflunomide has completed two phase III clinical trials for the treatment of RMS: TEMSO (O'Connor et al., 2011) and TOWER (Kappos et al., 2012) . In these studies, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) (31.5% and 36.3% versus placebo, respectively) and risk of 12-week sustained disability progression (29.8% and 31.5% versus placebo, respectively) in patients with RMS, while the 7 mg dose significantly reduced ARR (31.2% and 22.3% versus placebo) (O'Connor et al., 2011; Kappos et al., 2012) . While the antiThis article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from inflammatory mechanism of action of teriflunomide has been extensively studied in vitro, few in vivo studies have been carried out to date. Previous studies have shown that during EAE in the DA rat, changes in the latency and amplitude of somatosensory-evoked potentials (SSEPs) correspond to the disease phases when significant inflammation, demyelination and axonal loss occur pathologically (Merrill et al., 2009 ). Teriflunomide prevented EAE-associated electrophysiological changes in somatosensory pathways, and histologically, it decreased inflammation, demyelination and axonal loss (Merrill et al., 2009 ).
Motor-evoked potentials (MEPs) provide a quantitative measure of the neurophysiological status of descending motor tracts (Mazon Pelaez et al., 2005) . Transcranial magnetic stimulation (TMS) sends strong magnetic impulses directly into specific brain regions, inducing neurons to fire safely and painlessly (George, 2003) . In animal studies, magnetic stimulation applied over the skull stimulates the descending motor tracts, eliciting transcranial magnetic MEPs (tcMMEPs) in peripheral muscle (Magnuson et al., 1999) . TcMMEPs are altered in myelin-deficient mice, which demonstrate longer onset latencies and smaller amplitudes, compared with their wild-type counterparts (Zhang et al., 2007) . In humans, TMS has been used to study and/or potentially treat various diseases, including depression (Derstine et al., 2010; Fitzgerald and Daskalakis, 2011) , epilepsy (Brodbeck et al., 2010) , chronic pain (Antal et al., 2010) and spinal cord injury (Lefaucheur, 2006; Saturno et al., 2008) . In patients with MS, TMS-induced MEP conduction times are significantly more delayed than in controls (Magnuson et al., 1999) .
In this study, tcMMEPs were used to determine the neurophysiological deficits observed throughout EAE disease progression, and the functional effectiveness of prophylactic and Clinical signs of EAE disease were assessed daily in a non-blinded fashion, beginning on Day 5 post-EAE induction. Neurological deficits were scored according to the following scale: 0 = no clinical disease; 1 = flaccid tail; 2 = hindlimb weakness; 3 = hindlimb paresis; 4 = complete hindlimb paralysis; 5 = death due to EAE.
Compound administration and treatment regimens
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Transcranial magnetic stimulation
Magnetic stimulation was used for electrophysiological recordings and all experiments were conducted in restrained awake animals. Approximately 1 week prior to tcMMEPs, animals were handled daily and allowed to acclimatize to the restraint. The restraint fabric was placed over the rat such that the body was immobilized but the head, limbs and tail were exposed. Non-magnetic pins were used to attach the fabric to a wooden board, thus restraining the rat without inflicting injury or pain. After the rat was restrained, electromyography stainless steel needles (27 gauge; Ambu Inc., Glen Burnie, MD, USA) were inserted bilaterally into the gastrocnemius muscles.
Reference electrodes were inserted into the distal tendon ( Fig. 1a (Magnuson et al., 1999) ). A circular coil (40 mm) attached to a Magstim unit (Jali Medical Inc., Woburn, MA, USA) was placed over the head and a short magnetic pulse was delivered while electromyography responses were recorded. After threshold was obtained, the magnetic strength was increased in 20%
increments. In our studies, 60% magnetic output was sufficient to reach maximum response in the computerized CAST-Grid system (Olympus, Center Valley, PA, USA ), as described previously (Merrill et al., 2009 ).
Statistical analysis
A mixed-effects model using a robust covariance estimate was used to analyze the electrophysiology data, with the rank of latency to the specific peak (I, N) as the response, the rank of latency to the corresponding peak (I, N) at baseline as the covariate, treatment, disease stage, side (left and right hindlimbs) and their two-and three-way interactions as the fixed effects, and animal as the random effect. The Bonferroni-Holm method was used to adjust the multiplicity when comparing the EAE vehicle-treated group with the sham-treated and EAE-teriflunomide groups, respectively, at each disease stage. For the graphical representation of these data, the mean of the left and right sides of hindlimbs was plotted.
For the histology data, Wilcoxon's test was used to analyze the silver grain (damaged axons) data;
the Bonferroni-Holm method was used for multiplicity adjustment.
For the cumulative neurological score and maximum disease score, Wilcoxon's test was used to analyze the data; the Bonferroni-Holm method was used for multiplicity adjustment.
Results

Neurological deficits
Rats receiving daily administration of teriflunomide starting at Day 1 post-disease induction showed a complete suppression of EAE disease, compared with those receiving vehicle (Fig. 2a) .
The mean maximal neurological score (± standard error of the mean [SEM]) for vehicle-treated rats, 3.83 (± 0.09), occurred on Day 12 post-disease induction. The corresponding score in the teriflunomide-treated group at the same time was 0 (± 0).
Teriflunomide administered therapeutically daily, starting at onset of EAE disease symptoms, reduced neurological deficits at the acute-attack phase of EAE and demonstrated reduced disease severity throughout the observation period compared with that seen in vehicle-treated rats (Fig.   2b ). The mean maximal neurological score (± SEM) for vehicle-treated rats was 3.89 (± 0.12); this occurred on Day 12 post-disease induction. In teriflunomide-treated rats, the mean maximal neurological score was 1.85 (± 0.27), occurring on Day 11 post-disease induction. At the end of the experiment (Day 33 post-induction) there were greater residual deficits in vehicle-treated rats compared with teriflunomide-treated rats. This was reflected in a higher neurological score in this group (2.64 ± 0.47) compared with rats treated therapeutically with teriflunomide (0.44 ± 0.15).
Both prophylactic and therapeutic teriflunomide treatment of EAE rats significantly reduced cumulative neurological disease scores by 99.5% and 75.7%, respectively (p<0.0001 for both regimens), and maximum disease scores by 94.9% and 40.6%, respectively (p<0.0001 and p=0.0001), compared with those seen in vehicle-treated rats (Fig. 3) .
TcMMEP alterations
Latency delay may arise from inflammation, demyelination, conduction block, and/or axonal damage/loss. Example tcMMEP recordings from individual animals followed through various phases of EAE disease are shown in Fig. 4 and illustrate the increase in latency to onset of waveform response during the acute phase of EAE. A clear reduction in N-P amplitude is also observed, particularly during the acute and relapse phases of EAE, and to a lesser extent during disease remission. These changes are largely eliminated or reversed by prophylactic (a) or therapeutic (b) treatment with teriflunomide (Fig. 4) .
Latency to I and N
Compared with sham-treated animals, EAE rats treated with vehicle demonstrated significant alterations in tcMMEPs. Specifically, the latency to onset of waveform response (I) and first negative deflection (N) were significantly increased in these animals (Fig. 5a ). The latency to I was 0.0065 seconds pre-disease onset increasing to 0.0077 seconds during the acute phase of disease. Similarly, the latency to N increased from 0.0081 to 0.0093 seconds. Electrophysiological recordings demonstrated that prophylactic treatment with teriflunomide prevented a delay in the latency of waveform parameters (I and N) that occurred in vehicle-treated EAE animals. This effect was significant at Days 11, 18, 26 and 33 post-EAE disease induction, relating to the acute, remission and relapse-remission phases of the disease (Fig. 5a [i] and [ii]; p<0.05).
With therapeutic teriflunomide treatments, again, the vehicle-treated animals showed significant alterations in tcMMEPs. The latency to I was 0.0060 seconds pre-disease onset, which increased to compared with that seen in EAE vehicle-treated rats (Fig. 5b [i] ; p<0.05). Rats receiving therapeutic teriflunomide treatment also showed a greater effect on latency to N; a significant difference compared with EAE vehicle-treated rats was seen at Days 11, 18, 25 and 33 ( Fig. 5b [ii]; p<0.05).
N-P amplitude
A significant decrease in the amplitude of N-P was observed during the relapse phase (Days 25 and 33) of EAE disease in vehicle-treated animals, compared with sham-treated animals (p<0.05).
Prophylactic teriflunomide treatment prevented this decrease ( Fig. 6a; p<0.05 ).
In the therapeutic study, vehicle-treated animals showed a significant decrease in the amplitude of N-P at Day 25 post-EAE induction, compared with sham-treated animals (p<0.05), but the effect was not consistent at the second recorded time point during the relapse phase. This is probably a result of animals entering second relapse at different times, an effect not uncommon in the EAE disease model. Compared with EAE vehicle treatment, therapeutic teriflunomide treatment prevented this decrease and led to a significant increase in the amplitude of N-P at Days 11, 18 and 25 post-EAE induction ( Fig. 6b; p<0. 
05).
This article has not been copyedited and formatted. The final version may differ from this version. The DA rat model permits behavioral, functional and histopathological assessment of relapsingremitting EAE, which shows many pathological similarities to RMS in humans (McFarland and Martin, 2007) . The results presented here confirm previous findings demonstrating that prophylactic and therapeutic administration of teriflunomide reduces maximal and cumulative EAE disease scores, and that EAE rats demonstrated a delay in latency and a decrease in the amplitude of the SSEP (Merrill et al., 2009 ). The in vivo SSEP recordings used in the previous study had some limitations: the procedure was terminal, invasive and required use of anesthesia, which has been reported to affect evoked responses (Agrawal et al., 2009; Sloan et al., 2010) .
Conversely, the magnetic stimulation technique used in the current study is a non-invasive translational method that effectively measures MEP in awake, non-anesthetized rats (Linden et al., 1999; Zhang et al., 2007) . Passing a high-voltage current through a coil generates a magnetic field, which when placed in close proximity to inducible tissue such as the brain, will cause neurons to fire (Hovey, 2008; Bolognini and Ro, 2010) . The major advantage of using magnetic stimulation over electrical stimulation to evoke responses is that it does not require surgically implanted electrodes for longitudinal-type studies and is not painful when applied to the animal.
This article has not been copyedited and formatted. The final version may differ from this version. TcMMEPs have been used to evaluate neuronal transmission in animal models of spinal cord injury (Magnuson et al., 1999) and epilepsy (Vahabzadeh-Hagh et al., 2011) . This method is particularly well suited to the EAE model because it provides information on the physiological status of myelinated cortical motor neuronal projections and synaptic transmission (Mazon Pelaez et al., 2005) , which are functionally affected during inflammatory demyelination (Bannerman and Hahn, 2007; Vogt et al., 2009) . Another important benefit of this technique is that individual animal responses can be tracked throughout the course of the experiment, from pre-induction (baseline) through the progression of EAE disease. In this study, all recordings were performed in restrained, fully awake animals. For the first time, we were able to demonstrate that TMS is a valuable method to evaluate motor function in EAE-induced animals throughout all disease stages, and by using tcMMEPs as the endpoint in a longitudinal study we were able to demonstrate that teriflunomide improved motor deficits associated with EAE.
Teriflunomide treatment initiated 1 day post-disease induction (prophylactically), or at disease onset (therapeutically), reduced neurological deficits associated with EAE and prevented latency delays and amplitude changes in tcMMEPs. The most relevant findings of this study were the delay in latency of tcMMEPs in vehicle groups, but not in prophylactic or therapeutic teriflunomide-treated groups. Patients with MS exhibit a delay in the latency of TMS-induced MEPs, which correlates with disability (Michels et al., 1993; Schmierer et al., 2002; Conte et al., 2009; Kale et al., 2009) . Latency delays can result from inflammation and demyelination, and are observed during the acute, relapsing and remitting phases of EAE. During acute attack, inflammation is notable in various areas along the spinal cord of rats (unpublished results) and mice (Batoulis et al., 2012) . In humans, episodic neuritis (Plant, 2008 ) is observed in acute-stage MS. A decrease in amplitude is largely associated with axonal loss (Chalk et al., 1994; This article has not been copyedited and formatted. The final version may differ from this version. , 1995; Felts et al., 1997; Merrill et al., 2009 ). Subsequent to the deficits observed during the initial acute attack, most of the animals recorded at the first-remission phase of EAE in our study demonstrated an increase in amplitude in both teriflunomide-treated groups. During the remission phase of EAE, it has been reported that numerous regenerative and cell repair processes occur following the pro-inflammatory phase of EAE, which work to repair and/or enhance the survival of affected neurons (Zhu et al., 2003; Barbizan and Oliveira, 2010; Seger et al., 2010) . However, in EAE vehicle-treated animals, we observed a reduction in amplitude at first relapse and then a more notable reduction during the relapse-remission phase of EAE disease; this timeframe has been associated with increased axonal loss (Merrill et al., 2009 ).
There are limitations to this methodology, in particular with regard to assessing amplitude changes. Waveform amplitude is one of the most problematic indexes of waveform morphology, with common inter-and intra-subject variability. In addition, the synchrony of EAE disease progression becomes a major factor after the remission phase; relapse rates are highly individualized and the recording day may not coincide with the relapse phase of EAE.
Nevertheless, increases in amplitude were observed in animals receiving therapeutic teriflunomide and were maintained into the first relapse, while increases in amplitude in vehicle-treated animals were absent by the first relapse. Increases in amplitude were also observed during the relapseremission phase in animals receiving prophylactic teriflunomide, whereas vehicle-treated animals The data presented here extend our knowledge of teriflunomide in the EAE model. Together with data from previous studies (Merrill et al., 2009) TcMMEPs were recorded at baseline (prior to EAE induction), and at pre-illness, acute attack, remission, and relapse-remission phases of EAE Prophylactic study: for vehicle-treated rats, n = 12 at baseline, and Days 5 and 11; n = 11 at Days 18, 26 and 33; for teriflunomide-treated rats, n = 12 at all recording time points; for sham vehicletreated rats, n = 12 at baseline and Days 5, 11 and 18; n = 11 at Days 26 and 33
Therapeutic study: for vehicle-treated rats, n = 13 at baseline, and Days 5 and 11; n = 11 at Day 18; n = 12 at Days 26 and 33; for teriflunomide-treated rats, n = 13 at all recording time points; for This article has not been copyedited and formatted. The final version may differ from this version. 
